Vizenpistat

Overview

Vizenpistat (SR-8541A) is an orally active ENPP1 inhibitor. Vizenpistat increases cGAMP levels, blocks 2′3′-cGAMP hydrolysis, inhibits adenosine production, regulates innate immune signaling mediated by the STING pathway, and modulates anti-tumor immune responses. Vizenpistat is applicable to research related to breast cancer and metastatic microsatellite-stable colorectal cancer .

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > STING

Product Information

• Catalog No.: HY-176296
• CAS No.: 2687222-58-6
• Molecular Formula: C15H21N5O4S
• Molecular Weight: 367.42
• Purity: 99.14%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (6.80 mM); Clear solution
• Availability: In-stock

Source

Original product source